Both Rice University and the University of Houston were selected by the Department of Energy to receive funds for ongoing research projects. Photo via Getty Images

Rice University and the University of Houston were two of four national institutions to receive sizable grants from the Department of Energy last month to go toward the research and development of projects that will improve CO2 storage to help move the country toward the goal of net-zero emissions by 2050.

Each of the four projects works to advance long-term, commercial-scale geologic sequestration of CO2. According to a release from the DOE, the process of carbon capture and storage (known as CSS) separates and captures CO2 from the emissions of industrial processes before it is released into the atmosphere. Once captured, the CO2 is then injected into deep underground geologic formations, known as caprock.

However, during seismic events, like an earthquake or volcanic eruption, the CO2 can leak through the ground and contaminate the water supply.

"Large scale carbon capture efforts are vital to getting America emissions free by 2050, and how we store this CO2 must be safe, secure and permanent," said U.S. Secretary of Energy Jennifer M. Granholm. "The R&D investments in new tools and technology to monitor underground activity near CO2 storage sites will help us minimize risk from natural events like earthquakes, safeguard the environment and water supply, and get us that much closer to our clean energy goals."

Rice was awarded nearly $1.2 million from the DOE for its project that aims to develop a new strategy for monitoring seal integrity in the CCS process. The project "has the potential to provide a powerful platform for identifying CO2 leakage through reactivated faults or fracture zones," the statement said.

UH received a nearly $800,000 grant for its project that will work to determine cost-effective seismic data processing technologies that will automatically detect faults on 3D seismic migration images.

The project is being developed by Yingcai Zheng at the University of Houston in collaboration with Los Alamos National Lab and Vecta Oil and Gas and aims will help not only estimate seismic activity, but will also be able to estimate the fluid leakage pathways in certain regions, according to a separate release from UH.

"Most think of applied geophysics as linked to the oil and gas industry," Zheng said in the statement. "While that is true, when we think of the energy transition and how to achieve our goals, it is important to realize that this cannot happen without studying the geophysics of the subsurface – in a way, it literally holds the well-being of humanity's future."

The remaining two projects that received grants from the DOE come from the Battelle Memorial Institute in Ohio and The New Mexico Institute of Mining and Technology. In total the DOE issues $4 million to support the projects.

A number of Houston energy leaders are looking at smarter ways to store CO2. This spring, Joe Blommaert, the Houston-based president of ExxonMobil Low Carbon Solutions, said that he envisions creating a $100 billion carbon-capture hub along the Houston Ship Channel. And that same month Occidental's venture arm, Oxy Low Carbon Ventures, announced plans to construct and operate a pilot plant that would convert carbon dioxide into feedstocks.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”